52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION

Geert R. D'Haens  ¹     Remo Panaccione  ²     Julian Panés  ³     Tadakazu Hisamatsu  ⁴     Peter Bossuyt  ⁵     Silvio Danese  ⁶     Ezequiel Neimark  ⁷     Alexandra Song  ⁷     Xiaomei Liao  ⁷     Kori Wallace  ⁷     Javier Zambrano  ⁷     Rachel Duan  ⁷     Kristina Kligys  ⁷     Marla C. Dubinsky  ^8    
1 AMC Amsterdam Inflammatory Bowel Disease Centre - Academic Medical Center, AMC Amsterdam Inflammator, Amsterdam, Netherlands
² University of Calgary, Calgary, Canada
³ Hospital Clínic Barcelona, Barcelona, Spain
⁴ Kyorin University School of Medicine, Tokyo, Japan
⁵ Imelda General Hospital, Bonheiden, Belgium
⁶ Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy
⁷ AbbVie Inc., North Chicago, United States
⁸ Mount Sinai Hospital, Mount Sinai, New York City, United States

Topic
IBD, Nurses, Primary Care

Session
Clinical trials in Crohn's disease

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)